VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$28.83$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
SUPN logo

Supernus Pharmaceuticals, Inc.

SUPN
NASDAQ · Specialty & Generic Drugs
$28.83
At close - Nov 16, 4:00 PM EST - USD
Market Cap$3.52B
P/E7.8x
52W High$59.68
Volume3.67M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Lumpy Earnings Recovery Meets Balance Sheet Volatility

SUPN's revenue has rebounded from $149.8M in 2025Q1 to $356.0M in 2026Q3 on a consistently high gross margin of 84.6% to 90.1%, suggesting a durable high-margin product mix.

GrowthMixed
ProfitabilityModerate
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

SUPN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

-77% Peers

P/E is 77% below peer median

03

Market leadership

RS 20 · Lag

Laggard (Underperforming 80% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Jan 29

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
SUPN-25.29%
S&P 500 (^GSPC)+8.31%
1-Year Return
SUPN-18.03%
S&P 500 (^GSPC)+11.16%
3-Year Return
SUPN+32.57%
S&P 500 (^GSPC)+57.70%
5-Year Return
SUPN+8.01%
S&P 500 (^GSPC)+47.27%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
7.8x
Forward P/E
10.4x
EV/EBITDA0th %ile
6.0x
FCF YieldCash Flow
0.9%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
7.8x
30.3x
0th· Low
EV/EBITDA
6.0x
22.9x
0th· Low
Price/FCF
113.5x
14.1x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$40.88+41.8%
Base (Fair)$63.13+112.4%
Bull$94.36+227.3%
$40.88 Bear$63.13 Base$94.36 Bull
Current Market Price: $28.83
Trades at a 54.3% discount to Base DCF ($63.13)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.24B+4.3% YoY
Net income FY25
$210M+10400.0% YoY
Free cash flow FY25
-$94M-1980.0% YoY
Operating margin FY25
21.4%+18.7 pts YoY
ROIC (FY25)342.7%
Avg ROIC 5Y342.7%
ROE (FY25)-
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate11/12 (92%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 29, 2026
$1.32+24.5%
vs $1.06
$356M+8.1%
vs $329M
Q3 2026
Aug 3, 2026
$1.15+32.3%
vs $0.87
$343M+12.0%
vs $306M
Q2 2026
Apr 30, 2026
$0.96+50.0%
vs $0.64
$317M+16.2%
vs $273M
Q1 2026
Feb 26, 2026
$0.82+26.2%
vs $0.65
$358M+17.1%
vs $306M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 10, 2026
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.

Benzinga·Nov 9, 2026
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Defense World·Nov 6, 2026
Head-To-Head Review: Supernus Pharmaceuticals (NASDAQ:SUPN) and Chugai Pharmaceutical (OTCMKTS:CHGCY)

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Valuation and Earnings This table compares Chugai Pharmaceutical

247 Wallst·Nov 4, 2026
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More

Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.

Filtered for Supernus Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark SUPN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Supernus Pharmaceuticals, Inc. (SUPN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SUPN logoSUPNSupernus Pharmaceuticals, Inc.Current
$28.83$3.52B7.824.29%32.75%——
PCRX logoPCRXPacira BioSciences, Inc.
$36.48$1.43B39.483.63%5.08%5.53%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.67$3.2B9.0411.87%30.13%28.03%—
INVA logoINVAInnoviva, Inc.
$18.49$1.36B6.8918.52%43.79%15.84%—
PRGO logoPRGOPerrigo Company plc
$16.18$2.24B-1.27-2.75%-43.27%-68.13%7.11%
LNTH logoLNTHLantheus Holdings, Inc.
$101.72$6.62B25.780.5%17.28%21.72%—

Compare SUPN vs Peers

Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PCRX

Most directly comparable listed peer for SUPN.

Scale Benchmark

vs MCK

Larger-name benchmark to compare SUPN against a more recognizable public peer.

Peer Set

Compare Top 5

vs PCRX, ACAD, INVA, PRGO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

SUPN SEC Filings & Documents

Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Nov 2, 2026·SEC

Material company update

Oct 29, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 2, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 29, 2026·SEC

FY 2026

Oct 29, 2026·SEC

FY 2026

Aug 3, 2026·SEC

Get notified when SUPN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SUPN Frequently Asked Questions

Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Supernus Pharmaceuticals, Inc.'s revenue?

Supernus Pharmaceuticals, Inc. (SUPN) reported $1.37B in revenue over the trailing twelve months. Revenue was $1.24B in fiscal year 2025. That is 13839% more than the $8.9M of fiscal year 2008.

How fast is Supernus Pharmaceuticals, Inc. growing?

Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 16.3% over the trailing twelve months, compared with the twelve months before.

Is SUPN profitable?

Yes. Supernus Pharmaceuticals, Inc. (SUPN) earned $450.0M in net income over the trailing twelve months (a 32.8% net margin).

Dividend & Returns
What is Supernus Pharmaceuticals, Inc.'s free cash flow?

Supernus Pharmaceuticals, Inc. (SUPN) generated $31.0M in free cash flow over the trailing twelve months.

What if you invested $1,000 in SUPN back in 2008?

Total return calculator · dividends reinvested · 18+ years of data

See returns →